A J Eustace
Overview
Explore the profile of A J Eustace including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
138
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Eustace A, Madden S, Fay J, Collins D, Kay E, Sheehan K, et al.
Breast Cancer Res Treat
. 2021 May;
187(3):635-645.
PMID: 33983492
Background: Pre-treatment tumour-associated lymphocytes (TILs) and stromal lymphocytes (SLs) are independent predictive markers of future pathological complete response (pCR) in HER2-positive breast cancer. Whilst studies have correlated baseline lymphocyte levels...
2.
Mahgoub T, Eustace A, Collins D, Walsh N, ODonovan N, Crown J
Int J Oncol
. 2015 Jul;
47(3):900-8.
PMID: 26201960
Despite recent advances in targeted therapies and immunotherapies metastatic melanoma remains only rarely curable. The objective of the present study was to identify novel therapeutic targets for metastatic melanoma. A...
3.
Elster N, Collins D, Toomey S, Crown J, Eustace A, Hennessy B
Breast Cancer Res Treat
. 2014 Dec;
149(1):5-15.
PMID: 25542271
Approximately 20 % of human breast cancers (BC) overexpress HER2 protein, and HER2-positivity is associated with a worse prognosis. Although HER2-targeted therapies have significantly improved outcomes for HER2-positive BC patients,...
4.
Elster N, Cremona M, Morgan C, Toomey S, Carr A, OGrady A, et al.
Breast Cancer Res Treat
. 2014 Dec;
149(2):373-83.
PMID: 25528022
The PI3K pathway is a key mechanism of trastuzumab resistance, but early attempts to indirectly target this pathway with mTOR inhibitors have had limited success. We present the results of...
5.
Brougham D, Ivanova G, Gottschalk M, Collins D, Eustace A, OConnor R, et al.
J Biomed Biotechnol
. 2010 Oct;
2011:158094.
PMID: 20886062
We report the successful classification, by artificial neural networks (ANNs), of (1)H NMR spectroscopic data recorded on whole-cell culture samples of four different lung carcinoma cell lines, which display different...
6.
Eustace A, Mahgoub T, Tryfonopoulos D, ODonovan N, Crown J
J BUON
. 2010 Apr;
15(1):9-18.
PMID: 20414921
In 2006 there were 60,000 new cases of cutaneous melanoma in the European Union and 13,000 deaths (www.europeancancerleagues. org). Currently available systemic treatment options for metastatic melanoma, including both cytotoxic...
7.
Walsh N, Kennedy S, Larkin A, Tryfonopoulos D, Eustace A, Mahgoub T, et al.
Br J Cancer
. 2010 Mar;
102(7):1157-62.
PMID: 20234362
Background: Malignant melanoma, generally described as incurable, is notoriously refractory to chemotherapy. The mechanisms contributing to this have not yet been defined and the contributions of drug efflux pumps, implicated...
8.
Roberts D, Williams K, Cowen R, Barathova M, Eustace A, Brittain-Dissont S, et al.
Br J Cancer
. 2009 Sep;
101(8):1290-7.
PMID: 19755992
Background: Hypoxia is as an indicator of poor treatment outcome. Consistently, hypoxic HCT116 colorectal cancer cells are resistant to oxaliplatin, although the mechanistic basis is unclear. This study sought to...